| Results suggest reclassification of HER-2 proto-oncogene protein (cHER2+) tumors based on the spectrum of molecular breast cancer subtypes. | breast, |
| Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. | lung, |
| Data show that inhibition of S100 calcium binding protein P (S100P) results in reversing trastuzumab resistance (TzR) in proto-oncogene protein HER-2 (HER2)-driven breast cancers. | breast, |
| HER2 Transmembrane Domain Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers that are associated with Lung Adenocarcinoma. | lung, |
| ERBB2 oncogene at 17q12 is susceptible to palindromic gene amplification in HER2-positive breast tumors. | breast, |
| Findings suggest that the modulation of aberrant expression of miR-9, which in turn induces oncogenic Her-2 protein activity, might hold promise for preventive and therapeutic management of breast cancer (BC). | breast, |
| Patients with activating exon 20 HER2 mutations appear to have worse survival out- comes compared with other patients with lung adenocar- cinomas with oncogenic drivers. | lung, |
| Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. | breast, |
| Study showed for the first time that co-occuring oncogenic HER2 and mutant PIK3CA could induce replication stress in mammary epithelial cells and drives breast cancer progression. | breast, |
| Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. | pancreatic, |
| Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. | gastric, |
| Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. | breast, |
| Amplification and over-expression of the neu oncogene in human breast carcinomas. | breast, |
| Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. | breast, |
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | breast, |
| Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study. | prostate, |
| Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. | breast, |
| Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP. | gastric, |
| Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. | breast, |
| Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer. | breast, |